Recent Quotes
My Watchlist
Indicators
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

504.21 +43.34 (+9.41%)
Streaming Delayed Price Updated: 11:34 AM EDT, Mar 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
64 65 Next >
Top S&P500 movers in Tuesday's pre-market session ↗
Via Chartmill
News headline image
Nasdaq, S&P 500 Futures Turn Green On Iran War De-Escalation Signals: Why NVDA, ORCL, JOBY, VRTX, ZVRA Are On Traders' Radar Today ↗
Data from Stocktwits indicated that retail sentiment on SPY and QQQ was stabilizing. 
Via Stocktwits
Topics Artificial Intelligence ETFs Government
News headline image
VRTX Soars In Extended Hours After Experimental Drug Shows Positive Changes In Autoimmune Kidney Disease ↗
The company said that patients treated with povetacicept achieved a 52.0% reduction from baseline in urine protein to creatinine ratio at week 36, meeting the study’s key goal. 
Via Stocktwits
News headline image
Buying This 1 Biotech Stock Now Could Help Make You a Multimillionaire Retiree ↗
The company has performed well over the long run. 
Via The Motley Fool
Topics Intellectual Property Retirement
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Shows High Technical and Setup Ratings for Potential Breakout ↗
Via Chartmill
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Posts Mixed Q4 2025 Results, Provides 2026 Guidance ↗
Via Chartmill
News headline image
2 Biotech Giants to Buy in 2026 ↗
Both of these players are leaders in their fields. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Forget CRISPR Therapeutics: This Gene‑Editing Player Already Boasts the Profits It Dreams Of ↗
These two biotechs have a lot in common. Their differences are even more pronounced. 
Via The Motley Fool
News headline image
Is CRISPR Therapeutics Stock Too Risky to Buy Right Now? ↗
CRISPR isn't profitable, but it does have an approved gene therapy treatment with loads of potential. 
Via The Motley Fool
News headline image
2 Top Healthcare Stocks to Buy in February ↗
Patience should pay off with these two healthcare giants. 
Via The Motley Fool
News headline image
Forget Centessa Pharmaceuticals: This Rare‑Disease Specialist Has a Superior Portfolio and Pipeline ↗
One of these is not like the other. 
Via The Motley Fool
News headline image
Eli Lilly Bolsters Genetic Medicine Portfolio with $2.4 Billion Acquisition of Orna Therapeutics
In a definitive move to dominate the next frontier of immunology and oncology, Eli Lilly and Company (NYSE: LLY) announced on February 9, 2026, its acquisition of Orna Therapeutics for a total... 
Via MarketMinute
Topics Intellectual Property
News headline image
2 Nasdaq 100 Stocks Worth Your Attention and 1 We Question
The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a winner - some are struggling with slowing... 
Via StockStory
News headline image
The Ultimate Biotech Stock to Buy With $500 Right Now ↗
This biotech powerhouse could maintain its strength for the long term. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Could Vertex Stock Help Turn $100,000 Into $1 Million by 2036? ↗
Even a great stock has a ceiling. 
Via The Motley Fool
Topics Intellectual Property
News headline image
The Gene‑Therapy Breakthrough Story You'll Be Mad You Ignored at These Prices ↗
Forget Vertex Pharmaceuticals -- CRISPR Therapeutics is a better buy right now. 
Via The Motley Fool
Topics ETFs
News headline image
CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows ↗
Via MarketBeat
News headline image
5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q4 Earnings Call
Vertex Pharmaceuticals delivered fourth quarter results that outpaced Wall Street's revenue expectations, driven by continued expansion in cystic fibrosis therapies and early contributions from... 
Via StockStory
Topics Earnings
News headline image
1 S&P 500 Stock with Competitive Advantages and 2 We Turn Down
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some... 
Via StockStory
Topics Stocks
News headline image
Vertex: The Quiet Biotech Compounder I'd Happily Hold Through Any Market Crash ↗
Vertex has the revenue power to excel during any market environment. 
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
News headline image
Moderna’s mRNA Renaissance: Navigating Volatility and the Post-Pandemic Pipeline
As of February 17, 2026, Moderna, Inc. (NASDAQ:MRNA) finds itself at a pivotal crossroads in its corporate evolution. Long defined by its meteoric rise during the COVID-19 pandemic, the Cambridge-based... 
Via Finterra
Topics Economy Intellectual Property
News headline image
Sanofi Tightens Grip on Ocular Therapeutix with Revised Bid as Pivotal SOL-1 Trial Results Loom
In a move that could reshape the multi-billion-dollar retinal disease market, French pharmaceutical giant Sanofi (NASDAQ: SNY) has reportedly returned to the negotiating table with a significantly... 
Via MarketMinute
News headline image
Moderna, Vertex Pharmaceuticals, Integra LifeSciences, Baxter, and Molina Healthcare Shares Are Soaring, What You Need To Know
A number of stocks jumped in the afternoon session after a softer-than-expected inflation report fueled hopes for interest rate cuts by the Federal Reserve. The January Consumer Price Index (CPI), a... 
Via StockStory
Topics Economy
News headline image
The Blastoff-Ready Biotech Stock You'll Kick Yourself for Not Buying in 2026 ↗
2026 could be a big year for this company. 
Via The Motley Fool
Top S&P500 movers in Friday's session ↗
Via Chartmill
News headline image
Why CRISPR Therapeutics Stock Is Up Today (Despite Its Q4 Earnings Miss) ↗
A sales partner offered a ray of hope that this company couldn't for itself. 
Via The Motley Fool
Friday's session: top gainers and losers in the S&P500 index ↗
Via Chartmill
News headline image
Gilead Sciences and the 2026 Biotech Resurgence: A Leader in the Great Rotation
As of February 13, 2026, the financial markets are witnessing a historic "Great Rotation," where institutional capital is flowing out of overextended technology valuations and into the defensive,... 
Via MarketMinute
Topics Artificial Intelligence ETFs Government
News headline image
VRTX Q4 Deep Dive: Diversification Beyond Cystic Fibrosis Sets Stage for Next Growth Phase
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, with sales up 9.5% year on year to $3.19 billion. The company expects the full... 
Via StockStory
News headline image
Vertex (VRTX) Q4 2025 Earnings Call Transcript ↗
Vertex (VRTX) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
< Previous 1 2 3 4 5 6 7 8 9
...
64 65 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.